Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
met siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal, Intranasal, Inhalation, Subcutaneous, Topical, Transdermal, Oral, Parenteral
01
Overview
met siRNA (MET siRNA) is a small interfering RNA designed to selectively silence the expression of the MET proto-oncogene (hepatocyte growth factor receptor) via RNA interference (RNAi). MET is a receptor tyrosine kinase that, upon binding its ligand hepatocyte growth factor (HGF), activates downstream signaling pathways (such as PI3K/Akt and MAPK/ERK) involved in cell proliferation, survival, and migration. Aberrant MET activation or overexpression is associated with tumor progression, metastasis, and drug resistance in various cancers, including breast, gastric, and oral squamous cell carcinoma. met siRNA is primarily utilized as a research reagent in preclinical studies to investigate the role of MET signaling and to evaluate the therapeutic potential of MET knockdown in oncology.
- Other names
- MET siRNAMet-specific siRNAc-MET siRNA
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on met siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on met siRNA.